Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes

Gaurav Bharadwaj, Viet Nhan, Shan Chao Yang, Xiaocen Li, Anand Narayanan, Ana Carolina MacArenco, Yu Shi, Darrion Yang, Letícia Salvador Vieira, Wenwu Xiao, Yuanpei Li, Kit Lam

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Aim: To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG5K-CA8) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family. Materials & methods: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method. Results: Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1-6 μM), better hematocompatibility and lack of in vitro cytotoxicity. Conclusion: Along with PEG5K-CA8, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.

Original languageEnglish (US)
Pages (from-to)1153-1164
Number of pages12
JournalNanomedicine
Volume12
Issue number10
DOIs
StatePublished - May 1 2017

    Fingerprint

Keywords

  • cabazitaxel
  • cholic acid
  • docetaxel
  • drug delivery
  • micelle
  • nanoparticle
  • paclitaxel
  • taxane
  • telodendrimer

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Bioengineering
  • Biomedical Engineering
  • Development
  • Materials Science(all)

Cite this

Bharadwaj, G., Nhan, V., Yang, S. C., Li, X., Narayanan, A., MacArenco, A. C., Shi, Y., Yang, D., Vieira, L. S., Xiao, W., Li, Y., & Lam, K. (2017). Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes. Nanomedicine, 12(10), 1153-1164. https://doi.org/10.2217/nnm-2017-0361